Short description
VacV Biotech develops an oncolytic virus platform based on the vaccinia virus.
Description
VacV Biotherapeutics develops an oncolytic virus platform based on the vaccinia virus. The platform genetically modifies the oncolytic virus, which improves its specificity to tumors, reduces neurotoxicity, enhances the therapeutic effect, and greatly increases the production of extracellular enveloped virus (EEV). It has higher safety and efficiency and can be administered by intravenous injection.
Last funding
No Way
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
London, England, United Kingdom, Europe
Founded on
January 1, 2022
Non-profit?
No
Acquired?
No
Employees count
1-10
Investors
Noaccess
Sign in for full access